Peptide for AMD enters the clinic

Article

Potentia Pharmaceuticals has announced that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD).

Potentia Pharmaceuticals has announced that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD).

POT-4 is a synthetic peptide that binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is a central component of the major complement activation pathways, its inhibition effectively shuts down all downstream complement activation that could otherwise lead to inflammation, tissue damage and upregulation of angiogenic factors such as VEGF.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.